<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05622474</url>
  </required_header>
  <id_info>
    <org_study_id>B2022-589</org_study_id>
    <nct_id>NCT05622474</nct_id>
  </id_info>
  <brief_title>A Multicenter Randomized Controlled Clinical Study on the Treatment of T3N1M0 High Risk Nasopharyngeal Carcinoma With or Without Induction Chemotherapy Before Concurrent Radiotherapy and Chemotherapy</brief_title>
  <official_title>A Multicenter Randomized Controlled Clinical Study on the Treatment of T3N1M0 High Risk Nasopharyngeal Carcinoma With or Without Induction Chemotherapy Before Concurrent Radiotherapy and Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fifth Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First People's Hospital of Foshan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical trial is to compare the efficacy and safety of curative&#xD;
      radiotherapy with or without induction chemotherapy in patients with T3N1M0 nasopharyngeal&#xD;
      carcinoma. The main question[s] it aims to answer are:&#xD;
&#xD;
        -  Whether induction chemotherapy confers a survival benefit in patients with T3N1M0&#xD;
           nasopharyngeal carcinoma with high risks factors.&#xD;
&#xD;
        -  Whether induction chemotherapy worsens adverse effects in patients with T3N1M0&#xD;
           nasopharyngeal carcinoma.&#xD;
&#xD;
      Participants in experimental group will receive 3 cycles induction chemotherapy (GP or TPF)&#xD;
      followed by concurrent chemoradiotherapy.Participants in control group will receive&#xD;
      concurrent chemoradiotherapy only.&#xD;
&#xD;
      Researchers will compare FFS, OS and AE or SAE to see if patients can benefit from induction&#xD;
      chemotherapy or screen out high-risk factors associated with survival benefits.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, 236 patients with pathologically diagnosed nasopharyngeal carcinoma and&#xD;
      clinical stage of T3N1M0 will be randomly divided into two groups, 118 in the experimental&#xD;
      group (induction chemotherapy + concurrent chemoradiotherapy) and 118 in the control group&#xD;
      (concurrent chemoradiotherapy). The experimental group received 3 courses of induction&#xD;
      chemotherapy followed by radical radiotherapy for the nasopharynx and neck, and 2-3 courses&#xD;
      of cisplatin (100mg/m2, Q3W) treatment during radiotherapy. The control group received&#xD;
      radical radiotherapy for the nasopharynx and neck, and 2-3 courses of cisplatin (100mg/m2,&#xD;
      Q3W) during radiotherapy. Since there have been clinical trials to prove that GP or TPF&#xD;
      induction chemotherapy is effective in locally advanced nasopharyngeal carcinoma, the&#xD;
      induction chemotherapy regimen in this study can be selected by the investigator with GP or&#xD;
      TPF. During treatment and within 3 years after treatment, the efficacy and safety of patients&#xD;
      in both groups were followed up and evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2028</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Failure Free Survival</measure>
    <time_frame>Two years</time_frame>
    <description>The absence of relapse, non-relapse mortality or addition of another systemic therapythe last follow-up if there is no disease progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survial</measure>
    <time_frame>Two years</time_frame>
    <description>The time from randomization until death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">236</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>IC plus CC plus IMRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction chemotherapy followed by Intensity-modulated radiotherapy plus concurrent chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CC plus IMRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intensity-modulated radiotherapy plus concurrent chemotherapy alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Induction chemotherapy plus Concurrent chemotherapy</intervention_name>
    <description>Induction chemotherapy: TP( Docetaxel 75mg/m2, D1 and cisplatin 25 mg/m2, D1-3 every 3 weeks for 3 cycles) OR GP (Gemcitabine 1000mg/m2，D1,D8 and cisplatin 25 mg/m2, D1-3 every 3 weeks for 3 cycles）&#xD;
Concurrent chemotherapy: DDP -- Cisplatin 25 mg/m2, D1-3 , every 3 weeks for 2 cycles during radiation.</description>
    <arm_group_label>IC plus CC plus IMRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Concurrent chemotherapy</intervention_name>
    <description>Concurrent chemotherapy: DDP -- Cisplatin 25 mg/m2, D1-3 , every 3 weeks for 2 cycles during radiation.</description>
    <arm_group_label>CC plus IMRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT</intervention_name>
    <description>Radical radiation: Intensity-modulated radiotherapy</description>
    <arm_group_label>CC plus IMRT</arm_group_label>
    <arm_group_label>IC plus CC plus IMRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1.Pathologically diagnosed with stage T3N1M0 nasopharyngeal cancer according to 2017 AJCC&#xD;
        Cancer Staging Manual-8th Edition; not received anticancer treatment.&#xD;
&#xD;
        2.18-70 years old. 3. One or more of the following prognostic factors exist:&#xD;
&#xD;
          1. MRI showed extravasation of lymph node capsule,&#xD;
&#xD;
          2. MRI showed lymph node necrosis,&#xD;
&#xD;
          3. The maximum diameter of positive lymph nodes in the three-dimensional direction on MRI&#xD;
             is ≥ 3cm,&#xD;
&#xD;
          4. 2 or more positive lymph nodes,&#xD;
&#xD;
          5. Peripheral blood EBV-DNA ≥ 4000 copies/ml,&#xD;
&#xD;
          6. The maximum SUV value of lymph nodes on PET/CT ≥ 9.3. 4.ECOG Score (PS score) 0 or 1.&#xD;
             5.Neutrophil count &gt; 1.5*10^9/L, hemoglobin &gt; 90g/L, and platelet count &gt; 100*10^9/L.&#xD;
&#xD;
        6.ALT or AST level &lt; 2.5 times upper normal limit (upper limit of normal, ULN), bilirubin&#xD;
        level &lt; 1.5 times ULN.&#xD;
&#xD;
        7.Creatinine clearance level &gt; 60 ml/min. (Calculated according to Cockcroft Gault&#xD;
        formula).&#xD;
&#xD;
        8.Patients must sign an informed consent and must be willing and able to comply with the&#xD;
        visit, treatment protocol, laboratory tests and other requirements specified in the study&#xD;
        protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have other malignant tumors within 5 years, excluding carcinoma in situ,&#xD;
             well treated non melanoma skin cancer and papillary thyroid cancer.&#xD;
&#xD;
          2. Other conditions that may affect the safety or test compliance of the subject as&#xD;
             judged by the investigator, including symptomatic heart failure, unstable angina,&#xD;
             myocardial infarction, active infection requiring systemic treatment, mental illness&#xD;
             or family and social factors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fang-Yun Xie, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fang-Yun Xie, M.D</last_name>
    <phone>+86-020-87342618</phone>
    <email>xiefy@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pu-Yun OuYang, M.D</last_name>
    <phone>+86-020-87342618</phone>
    <email>ouyangpy@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 13, 2022</study_first_submitted>
  <study_first_submitted_qc>November 17, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2022</study_first_posted>
  <last_update_submitted>November 17, 2022</last_update_submitted>
  <last_update_submitted_qc>November 17, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Fang-Yun Xie</investigator_full_name>
    <investigator_title>Sun Yat-sen University Cancer Center</investigator_title>
  </responsible_party>
  <keyword>Nasopharyngeal Carcinoma</keyword>
  <keyword>T3N1M0</keyword>
  <keyword>Induction Chemotherapy</keyword>
  <keyword>Concurrent Chemoradiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

